Plain-English translation of NCT06560112 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a combination of two new medications called and —sometimes given together with —can help treat ovarian cancer that has come back after previous treatment. These are immunotherapy medications designed to help your body's immune system fight the cancer. The trial will look at how well different combinations work and how safe they are.
Ovarian cancer often returns even after initial treatment, and patients need better options. This medication is being tested to see if it can help control recurring disease in women who may no longer be able to receive their previous treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly (typically every 3 to 6 weeks depending on which treatment group you're in) to receive your medication infusions and have blood tests and scans to monitor how you're responding. You would also need to provide a sample of your tumor tissue so researchers can study it. The study will continue until the medication is no longer helping or side effects become too difficult to manage.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Akeso
Enrollment target
~172 participants
Started
November 2024
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Liu, M.D.
Akeso
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.